GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market